Patent ID: 9643995
Date: 2017-05-09
CPC Classifications: A61K,C07J,C07K

Claim:
1. A method of treating cancer in a patient in need thereof with the administration of nanoparticles of wherein MBS is a maleimidobenzoyl-N-hydroxy sulfosuccinimide ester activated antibody, wherein the sulfo-MBS activated antibody is anti-Her2; wherein the  is a poly(DL-lactic acid) nanoparticle loaded with triterpene glycoside or triterpene, wherein □ is a chemotherapeutic agent and wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, 5-FU, trastuzumab, tamoxifen, sulindac sulfide, thapsigargin and MEK inhibitor U0126; and wherein the cancer is selected from the group consisting of breast, prostate, oral, skin, colon and liver cancer.